Medical Castration with Zoladex: A Conservative Approach to Premenopausal Breast Cancer

@article{Brambilla1991MedicalCW,
  title={Medical Castration with Zoladex: A Conservative Approach to Premenopausal Breast Cancer},
  author={Cristina Brambilla and A. Escobedo and R Artioli and Mar{\'i}a Jos{\'e} Lechuga and Manuela Motta and Gianni Bonadonna},
  journal={Tumori Journal},
  year={1991},
  volume={77},
  pages={145 - 150}
}
For almost a century surgical castration represented the initial standard therapy for metastatic breast cancer in premenopausal women with hormone dependent tumors. Today the suppression of ovarian function can also be obtained by the administration of supraphysiologic doses of luteinizing hormone releasing hormone (LHRH) agonists. From April 1987 to February 1989, 23 premenopausal patients with advanced breast cancer (median age 39 years, range 28-52, ER positive 20, unknown 3; prior… 

Figures and Tables from this paper

Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.
TLDR
It is confirmed prospectively that the efficacy of chemical castration is comparable to that of oophorectomy (or ovarian irradiation), and the concurrent use of tamoxifen can probably enhance the activity of goserelin, but it also induces more side effects.
Phase II study of goserelin for patients with postmenopausal metastatic breast cancer.
  • T. SaphnerA. Troxel M. Abeloff
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
GN-RH agonists have activity in ER+ postmenopausal patients, but response rates are not as high as with other available endocrine therapies and the duration of response is short.
Ovarian Function Suppression with the Gonadotrophin-Releasing Hormone (GnRH) Analogue Goserelin in Premenopausal Advanced Breast Cancer
TLDR
It is confirmed that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer and the best responses were observed on soft tissues.
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients
TLDR
It is indicated that the two formulations exert a comparable estrogen-suppressive effect and warrant further study of the 3-monthly formulation of leuprolide acetate in breast cancer patients.
Successful co‐treatment with LHRH‐agonist for ovarian over‐stimulation and cystic formation in premenopausal tamoxifen exposure
TLDR
It is concluded that short duration of co‐treatment with long acting LHRH‐agonist administered to premenopausal breast cancer patients treated with tamoxifen, successfully resolved the tamoxIFen‐induced supraphysiological serum 17β estradiol levels and the ovarian cysts.
Management of metastatic breast cancer
TLDR
The role of high dose chemotherapy with autologous bone marrow transplantation remains a promising area of investigation, but the available survival data are entirely compatible with the possibility that this modality will eventually prove inferior to conventional therapy.
Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients With Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study
TLDR
The present study failed to demonstrate a 15% difference in RFS in favor of node-positive premenopausal patients treated with an additional 5 years of tamoxifen after CNF adjuvant chemotherapy and ovarian ablation.
Section Review: Oncologic, Endocrine & Metabolic: New treatment approaches for metastatic breast cancer
TLDR
The expanding knowledge of molecular cancer pathogenesis is leading to the identification of new drug targets and novel treatment approaches in breast cancer, and hormonal agents in development for use in metastatic breast cancer include new anti-oestrogens, anti-progestins, aromatase inhibitors and gonadotrophin-releasing hormone agonists.
Endocrine therapy for advanced breast cancer.
  • P. ShahM. Dickler
  • Medicine, Biology
    Clinical advances in hematology & oncology : H&O
  • 2014
TLDR
These are the various landmark trials that have established current standards of practice in the management of patients with hormone receptor-positive metastatic breast cancer and a discussion of future directions and ongoing studies is provided.
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
  • C. TaylorS. Green C. Osborne
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
The study was initially designed as an equivalence trial with 80% power to rule out a 50% improvement in survival due to ovariectomy, but accrual was slow and the study was terminated early, which resulted in a final power of 60% for the alternative hypothesis of equal survival distributions.
...
...

References

SHOWING 1-10 OF 30 REFERENCES
Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer.
TLDR
It is concluded that this GnRH analogue provides a safe and effective means of producing medical castration in premenopausal patients with metastatic breast carcinoma.
Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments
  • J. Klijn
  • Medicine, Biology
    Medical oncology and tumor pharmacotherapy
  • 1984
TLDR
Of the whole group of 21 patients, 9 patients showed an objective remission, 6 stable disease and 6 progression of tumour growth, which was not found during combination treatment with megestrol acetate in 4 patients.
Salvage treatments in relapsing resectable breast cancer.
TLDR
There is convincing evidence that the natural history of resectable breast cancer can be perturbed by adjuvant medical intervention, which was reflected in a highly significant reduction in the odds of death following adjUvant chemotherapy, especially in premenopausal women.
Endocrine therapy of breast cancer.
Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
TLDR
The use of depot preparation of an LHRH analogue to suppress gonadotrophin and sex hormone secretion offers the convenience of once monthly injections when L HRH analogues are required for the long term treatment of elderly patients with prostatic cancer and children with precocious puberty.
Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women.
TLDR
Changes of BA LH appeared to be responsible for the suppression of ovarian androgen secretion during GnRH-a treatment and in turn may have contributed to the profound decreases of estrogen production by reducing the amount of precursor androgen available for aromatization.
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist
TLDR
Major direct effects of LHRH and its agonists on the growth of breast tumour cells in culture are reported, indicating that these agonists could have direct antitumour effects.
The use of endocrine therapy.
...
...